LXRX: Lexicon Pharmaceuticals, Inc. Stock

by  •  • Comments Off on LXRX: Lexicon Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 255.14
Enterprise Value ($M) 96.67
Book Value ($M) 178.51
Book Value / Share 0.49
Price / Book 1.43
NCAV ($M) 115.76
NCAV / Share 0.32
Price / NCAV 2.20

Profitability (mra)
Return on Invested Capital (ROIC) -0.76
Return on Assets (ROA) -0.94
Return on Equity (ROE) -2.29

Liquidity (mrq)
Quick Ratio 7.15
Current Ratio 7.17

Balance Sheet (mrq) ($M)
Current Assets 258.37
Assets 321.12
Liabilities 142.61
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
12-09 13D/A Invus, L.P. 37.70 0.00
11-14 13G/A Biotechnology Value Fund L P 0.00 -100.00
11-12 13G/A Fmr Llc 13.79 28.90

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 5,451,051 8,352,021 65.27
2025-01-13 6,316,546 10,310,736 61.26
2025-01-10 4,111,471 6,518,058 63.08

(click for more detail)

Similar Companies
KURA – Kura Oncology, Inc. KYTX – Kyverna Therapeutics, Inc.
LVTX – LAVA Therapeutics N.V. LYEL – Lyell Immunopharma, Inc.
MCRB – Seres Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io